IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations

Molecular-Docking-Based Anti-Allergic Drug Design

Molecular-Docking-Based Anti-Allergic Drug Design
View Sample PDF
Author(s): Anamika Basu (Gurudas College, India), Piyali Basak (Jadavpur University, India)and Anasua Sarkar (Jadavpur University, India)
Copyright: 2017
Pages: 16
Source title: Pharmaceutical Sciences: Breakthroughs in Research and Practice
Source Author(s)/Editor(s): Information Resources Management Association (USA)
DOI: 10.4018/978-1-5225-1762-7.ch027

Purchase

View Molecular-Docking-Based Anti-Allergic Drug Design on the publisher's website for pricing and purchasing information.

Abstract

Allergens are foreign proteins that when come in contact of part(s) of human body stimulate the production of immunoglobulin types of proteins (antibodies). These allergens react with antibodies (immunoglobulin type E or IgE) produces allergic reactions, also known as immediate-type hypersensitivity reactions. As much as 20% of the general population may be affected by grass pollen as a major cause of allergic disease. EXPB class of proteins are known in the immunological literature as group-1 grass pollen allergens Molecular docking method can be used to identify the predicated the interaction of pollen allergen EXPB1 (Zea m 1), a beta-expansin and group-1 pollen allergen from maize with IgE molecules of human. The World Health Organization recognised allergen immunotherapy, as therapeutics for allergic diseases. RNA Interference (RNAi) is a biological process in which RNA molecules e.g. Small Interfering RNAs (siRNAs) inhibit gene expression, by cleavage and destruction of specific mRNA molecules. Use of Small Interfering RNA (siRNA) is a novel method in the induction of RNA Interference (RNAi), which is a potent method for therapeutics of allergic reactions. Due to various effects of STAT 6 proteins during hypersensitivity reactions caused by pollen allergens, mRNA of STAT6 gene is selected as target gene for allergy therapeutics via Post-Transcriptional Gene Silencing (PTGS). Using molecular docking study a specific sense siRNA is identified as anti allergic drug to treat allergic asthma during immediate type of hypersensitivity reaction, caused by Zea m 1 pollen allergen.

Related Content

Abul Kalam Azad, Mohamad Dayoob, Fatema Tuz Zohera. © 2024. 21 pages.
W. H. P. A. D. Perera, Mithuni N. Senadeera, Dinusha N. Udukala. © 2024. 26 pages.
Thi Van Anh Nguyen, Trang Nguyen Ngoc, Thanh Tung Bui. © 2024. 43 pages.
Abul Kalam Azad, Mallari Praveen, Wan Mohd Azizi Bin Wan Sulaiman. © 2024. 31 pages.
Bancha Yingngam. © 2024. 43 pages.
Babi Lakkoju, Swapna Asuthkar, Gundla Rambabu, Kolli Balakrishna. © 2024. 20 pages.
Arthi Gunasekaran, Trisha Sathya, Vijaya Anand Arumugam, Balamuralikrishnan Balasubramanian, Asirvatham Alwin Robert, Arun Meyyazhagan. © 2024. 31 pages.
Body Bottom